ClinicalTrials.gg
CompletedNCT05917288Updated Nov 14, 2025Results posted

A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus Erythematosus

A Phase 1 interventional study of Belimumab and Standard of care in Systemic Lupus Erythematosus, sponsored by GlaxoSmithKline. Completed at 6 sites in China. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-11-14.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.

Enrollment
32nd of 36
16 · median 81
Started
2023
the only one that year
Phase 1
7 of 36
none open now
Registered
32nd of 36
by date
Lead sponsor
13 of 36
GlaxoSmithKline

Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 32nd largest by enrollment, is the only one that started in 2023, is one of 7 in phase 1, and was the 32nd registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About belimumab

belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing belimumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

This study will evaluate the pharmacokinetic characteristics and safety of belimumab subcutaneous (SC) in Chinese pediatric participants with SLE who have completed 48 weeks belimumab Intravenous (IV) treatment in 213560 study (NCT04908865)

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Belimumab
  • Pediatric
  • Pharmacokinetics
  • Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants between 5 and 17 years of age inclusive, at the time of
  • Chinese pediatric participants with SLE, who have completed 48 weeks treatment in study 213560 and who, in the opinion of the investigator, may benefit from treatment with GSK1550188.
  • Body weight greater than equal to >=15 kilograms (kg), at the time of signing the informed consent.
  • Male and/or female:

    1. No measures are required for male participants.
    2. Female participants: A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:

    i) Is a woman of non- OR ii) Is a woman of childbearing potential and using a contraceptive method that is highly effective, with a failure rate of \<1%

  • Participant signs and dates a written age-appropriate assent form (in accordance with applicable regulations) and the parent or legal guardian (or emancipated minor) that has the ability to understand the requirements of the study, provides written informed consent (including consent for the use and disclosure of research-related health information) that the participant will comply with the study protocol procedures (including required study visits).

Exclusion criteria

Exclusion Criteria:

  • Participants who have developed clinical evidence of significant, unstable or uncontrolled, acute or chronic diseases not due to SLE (i.e., cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological, or infectious diseases), or experienced an Adverse events (AE) in 213560 study that could, in the opinion of the principal investigator, put the participant at undue risk.
  • Have developed any other medical diseases (e.g., cardiopulmonary), laboratory abnormalities, or conditions that, in the opinion of the principal investigator, makes the participant unsuitable for the study.
  • Have an estimated as calculated by Schwartz Formula of less than 30 milliliter per minute (mL/min).
  • Have an Immunoglobulin A (IgA) deficiency (IgA level \<10 milli gram per deciliter [mg/dL]).
  • Have a Grade 3 or greater laboratory abnormality based on the protocol toxicity scale except for the following that are allowed:

    1. Stable Grade 3 hypoalbuminemia due to lupus nephritis and not related to liver disease or malnutrition.
    2. Any grade proteinuria
    3. Stable Grade 3 gamma glutamyl transferase (GGT) elevation due to lupus hepatitis and not related to alcoholic liver disease, uncontrolled diabetes or viral hepatitis. If present, any abnormalities in the (ALT) and/or aspartate aminotransferase (AST) must be \<= Grade 2.
    4. Stable Grade 3 neutropenia; or stable Grade 3 lymphopenia; or stable Grade 3 leukopenia, due to SLE.
  • Developing a positive test for (HIV) antibody after inclusion into 213560, per investigator's discretion according to clinical need.
  • Developing : Serologic evidence of Hepatitis B (HB) infection defined as Hepatitis B surface antigen positive (HBsAg+) OR Hepatitis B core antibody positive (HBcAb+) after inclusion into 213560, per investigator's discretion according to clinical need.
  • Developing a positive test for antibody after inclusion into 213560, per investigator's discretion according to clinical need.
  • Have received a live or within 30 Days of Day 1.
  • Are unable or unlikely, in the opinion of the investigator, to administer belimumab by SC injection and have no reliable source to administer the injection.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Participants receiving belimumab + Standard of care (SOC)

    Participants will receive belimumab 200 milligrams SC injection according the Baseline body weight plus SOC.

    Biological: Belimumab · Drug: Standard of care

Interventions

  • BiologicalBelimumab

    Belimumab will be administered

  • DrugStandard of care

    Standard of care will be administered

06

What researchers measure

Primary outcomes

  1. Area Under the Curve at Steady-state to the End of the Dosing Period (AUCss,0-tau) of Belimumab for Participants Weighing Greater Than or Equal to (>=) 50 Kilograms (kg)

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of belimumab. AUCss,0-tau of belimumab for participants weighing \>= 50 kg has been reported. As the first dose of belimumab was administered on Day 1, Week 12 post-dose correlates to Day 1 plus 84 days, i.e., Day 85.

    Time frame: Pre-dose on Days 1, 8, and 78, and post-dose on Days 4, 81, and 85

  2. Area Under the Curve at Steady-state to the End of the Dosing Period (AUCss,0-tau) of Belimumab for Participants Weighing Between 30 kg and Less Than (<) 50 kg

    Blood samples were collected at indicated time points for PK analysis of belimumab. AUCss,0-tau of belimumab for participants weighing between 30 kg and \< 50 kg has been reported.

    Time frame: Pre-dose on Days 1, 11, and 71, and post-dose on Days 4, 74, and 81

  3. Area Under the Curve at Steady-state to the End of the Dosing Period (AUCss,0-tau) of Belimumab for Participants Weighing Between 15 kg and < 30 kg

    Blood samples were collected at indicated time points for PK analysis of belimumab. AUCss,0-tau of belimumab for participants weighing between 15 kg and \< 30 kg has been reported. As the first dose of belimumab was administered on Day 1, Week 12 post-dose correlates to Day 1 plus 84 days, i.e., Day 85.

    Time frame: Pre-dose on Days 1, 15, and 71, and post-dose on Days 4, 74, and 85

  4. Average Serum Concentration at Steady State (Cavg,ss) of Belimumab for Participants Weighing >= 50 kg

    Blood samples were collected at indicated time points for PK analysis of belimumab. Cavg,ss of belimumab for participants weighing \>= 50 kg has been reported. As the first dose of belimumab was administered on Day 1, Week 12 post-dose correlates to Day 1 plus 84 days, i.e., Day 85.

    Time frame: Pre-dose on Days 1, 8, and 78, and post-dose on Days 4, 81, and 85

  5. Average Serum Concentration at Steady State (Cavg,ss) of Belimumab for Participants Weighing Between 30 kg and < 50 kg

    Blood samples were collected at indicated time points for PK analysis of belimumab. Cavg,ss of belimumab for participants weighing between 30 kg and \< 50 kg has been reported.

    Time frame: Pre-dose on Days 1, 11, and 71, and post-dose on Days 4, 74, and 81

  6. Average Serum Concentration at Steady State (Cavg,ss) of Belimumab for Participants Weighing Between 15 kg and < 30 kg

    Blood samples were collected at indicated time points for PK analysis of belimumab. Cavg,ss of belimumab for participants weighing between 15 kg and \< 30 kg has been reported. As the first dose of belimumab was administered on Day 1, Week 12 post-dose correlates to Day 1 plus 84 days, i.e., Day 85.

    Time frame: Pre-dose on Days 1, 15, and 71, and post-dose on Days 4, 74, and 85

  7. Minimum Serum Concentration at Steady State (Cmin,ss) of Belimumab for Participants Weighing >= 50 kg

    Blood samples were collected at indicated time points for PK analysis of belimumab. Cmin,ss of belimumab for participants weighing \>= 50 kg has been reported. As the first dose of belimumab was administered on Day 1, Week 12 post-dose correlates to Day 1 plus 84 days, i.e., Day 85.

    Time frame: Pre-dose on Days 1, 8, and 78, and post-dose on Days 4, 81, and 85

  8. Minimum Serum Concentration at Steady State (Cmin,ss) of Belimumab for Participants Weighing Between 30 kg and < 50 kg

    Blood samples were collected at indicated time points for PK analysis of belimumab. Cmin,ss of belimumab for participants weighing 30 kg and \< 50 kg has been reported.

    Time frame: Pre-dose on Days 1, 11, and 71, and post-dose on Days 4, 74, and 81

  9. Minimum Serum Concentration at Steady State (Cmin,ss) of Belimumab for Participants Weighing Between 15 kg and < 30 kg

    Blood samples were collected at indicated time points for PK analysis of belimumab. Cmin,ss of belimumab for participants weighing 15 kg and \< 30 kg has been reported. As the first dose of belimumab was administered on Day 1, Week 12 post-dose correlates to Day 1 plus 84 days, i.e., Day 85.

    Time frame: Pre-dose on Days 1, 15, and 71, and post-dose on Days 4, 74, and 85

  10. Maximum Serum Concentration During the Dosing Interval at Steady State (Cmax,ss) of Belimumab for Participants Weighing >= 50 kg

    Blood samples were collected at indicated time points for PK analysis of belimumab. Cmax,ss of belimumab for participants weighing \>= 50 kg has been reported. As the first dose of belimumab was administered on Day 1, Week 12 post-dose correlates to Day 1 plus 84 days, i.e., Day 85.

    Time frame: Pre-dose on Days 1, 8, and 78, and post-dose on Days 4, 81, and 85

  11. Maximum Serum Concentration During the Dosing Interval at Steady State (Cmax,ss) of Belimumab for Participants Weighing Between 30 kg and < 50 kg

    Blood samples were collected at indicated time points for PK analysis of belimumab. Cmax,ss of belimumab for participants weighing between 30 kg and \< 50 kg has been reported.

    Time frame: Pre-dose on Days 1, 11, and 71, and post-dose on Days 4, 74, and 81

  12. Maximum Serum Concentration During the Dosing Interval at Steady State (Cmax,ss) of Belimumab for Participants Weighing Between 15 kg and < 30 kg

    Blood samples were collected at indicated time points for PK analysis of belimumab. Cmax,ss of belimumab for participants weighing between 15 kg and \< 30 kg has been reported. As the first dose of belimumab was administered on Day 1, Week 12 post-dose correlates to Day 1 plus 84 days, i.e., Day 85.

    Time frame: Pre-dose on Days 1, 15, and 71, and post-dose on Days 4, 74, and 85

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), and AEs of Special Interest (AESIs) Through Week 12

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in the offspring of a study participant; or other situations as per medical and scientific judgement of the Investigator. AESIs defined in the protocol included post-injection systemic reactions and hypersensitivity reactions, infections of special interest, malignancies, and depression, suicidality, or self-injury. Number of participants with AEs, SAEs, and AESIs has been reported.

    Time frame: Up to Week 12

07

Results

Posted Nov 14, 2025

Participant flow

A total of 16 participants were enrolled in this study.

Participant flow — Overall Study
MilestoneBelimumab 200 mg/mL
Started16
Completed16
Not completed0

Outcome measures

PrimaryArea Under the Curve at Steady-state to the End of the Dosing Period (AUCss,0-tau) of Belimumab for Participants Weighing Greater Than or Equal to (>=) 50 Kilograms (kg)

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of belimumab. AUCss,0-tau of belimumab for participants weighing \>= 50 kg has been reported. As the first dose of belimumab was administered on Day 1, Week 12 post-dose correlates to Day 1 plus 84 days, i.e., Day 85.

Time frame:
Pre-dose on Days 1, 8, and 78, and post-dose on Days 4, 81, and 85
Reported as:
Geometric mean · Days*micrograms per milliliter
Area Under the Curve at Steady-state to the End of the Dosing Period (AUCss,0-tau) of Belimumab for Participants Weighing Greater Than or Equal to (>=) 50 Kilograms (kg)
Days*micrograms per milliliterBelimumab 200 mg/mL Every Week
Area Under the Curve at Steady-state to the End of the Dosing Period (AUCss,0-tau) of Belimumab for Participants Weighing Greater Than or Equal to (>=) 50 Kilograms (kg)633.26 ± 27.50
PrimaryArea Under the Curve at Steady-state to the End of the Dosing Period (AUCss,0-tau) of Belimumab for Participants Weighing Between 30 kg and Less Than (<) 50 kg

Blood samples were collected at indicated time points for PK analysis of belimumab. AUCss,0-tau of belimumab for participants weighing between 30 kg and \< 50 kg has been reported.

Time frame:
Pre-dose on Days 1, 11, and 71, and post-dose on Days 4, 74, and 81
Reported as:
Geometric mean · Days*micrograms per milliliter
Area Under the Curve at Steady-state to the End of the Dosing Period (AUCss,0-tau) of Belimumab for Participants Weighing Between 30 kg and Less Than (<) 50 kg
Days*micrograms per milliliterBelimumab 200 mg/mL Every 10 Days
Area Under the Curve at Steady-state to the End of the Dosing Period (AUCss,0-tau) of Belimumab for Participants Weighing Between 30 kg and Less Than (<) 50 kg807.57 ± 17.44
PrimaryArea Under the Curve at Steady-state to the End of the Dosing Period (AUCss,0-tau) of Belimumab for Participants Weighing Between 15 kg and < 30 kg

Blood samples were collected at indicated time points for PK analysis of belimumab. AUCss,0-tau of belimumab for participants weighing between 15 kg and \< 30 kg has been reported. As the first dose of belimumab was administered on Day 1, Week 12 post-dose correlates to Day 1 plus 84 days, i.e., Day 85.

Time frame:
Pre-dose on Days 1, 15, and 71, and post-dose on Days 4, 74, and 85
Reported as:
Geometric mean · Days*micrograms per milliliter
Area Under the Curve at Steady-state to the End of the Dosing Period (AUCss,0-tau) of Belimumab for Participants Weighing Between 15 kg and < 30 kg
Days*micrograms per milliliterBelimumab 200 mg/mL Every 2 Weeks
Area Under the Curve at Steady-state to the End of the Dosing Period (AUCss,0-tau) of Belimumab for Participants Weighing Between 15 kg and < 30 kg1365.23 ± NA
PrimaryAverage Serum Concentration at Steady State (Cavg,ss) of Belimumab for Participants Weighing >= 50 kg

Blood samples were collected at indicated time points for PK analysis of belimumab. Cavg,ss of belimumab for participants weighing \>= 50 kg has been reported. As the first dose of belimumab was administered on Day 1, Week 12 post-dose correlates to Day 1 plus 84 days, i.e., Day 85.

Time frame:
Pre-dose on Days 1, 8, and 78, and post-dose on Days 4, 81, and 85
Reported as:
Geometric mean · Micrograms per milliliter
Average Serum Concentration at Steady State (Cavg,ss) of Belimumab for Participants Weighing >= 50 kg
Micrograms per milliliterBelimumab 200 mg/mL Every Week
Average Serum Concentration at Steady State (Cavg,ss) of Belimumab for Participants Weighing >= 50 kg90.47 ± 27.50
PrimaryAverage Serum Concentration at Steady State (Cavg,ss) of Belimumab for Participants Weighing Between 30 kg and < 50 kg

Blood samples were collected at indicated time points for PK analysis of belimumab. Cavg,ss of belimumab for participants weighing between 30 kg and \< 50 kg has been reported.

Time frame:
Pre-dose on Days 1, 11, and 71, and post-dose on Days 4, 74, and 81
Reported as:
Geometric mean · Micrograms per milliliter
Average Serum Concentration at Steady State (Cavg,ss) of Belimumab for Participants Weighing Between 30 kg and < 50 kg
Micrograms per milliliterBelimumab 200 mg/mL Every 10 Days
Average Serum Concentration at Steady State (Cavg,ss) of Belimumab for Participants Weighing Between 30 kg and < 50 kg80.76 ± 17.44
PrimaryAverage Serum Concentration at Steady State (Cavg,ss) of Belimumab for Participants Weighing Between 15 kg and < 30 kg

Blood samples were collected at indicated time points for PK analysis of belimumab. Cavg,ss of belimumab for participants weighing between 15 kg and \< 30 kg has been reported. As the first dose of belimumab was administered on Day 1, Week 12 post-dose correlates to Day 1 plus 84 days, i.e., Day 85.

Time frame:
Pre-dose on Days 1, 15, and 71, and post-dose on Days 4, 74, and 85
Reported as:
Geometric mean · Micrograms per milliliter
Average Serum Concentration at Steady State (Cavg,ss) of Belimumab for Participants Weighing Between 15 kg and < 30 kg
Micrograms per milliliterBelimumab 200 mg/mL Every 2 Weeks
Average Serum Concentration at Steady State (Cavg,ss) of Belimumab for Participants Weighing Between 15 kg and < 30 kg97.52 ± NA
PrimaryMinimum Serum Concentration at Steady State (Cmin,ss) of Belimumab for Participants Weighing >= 50 kg

Blood samples were collected at indicated time points for PK analysis of belimumab. Cmin,ss of belimumab for participants weighing \>= 50 kg has been reported. As the first dose of belimumab was administered on Day 1, Week 12 post-dose correlates to Day 1 plus 84 days, i.e., Day 85.

Time frame:
Pre-dose on Days 1, 8, and 78, and post-dose on Days 4, 81, and 85
Reported as:
Geometric mean · Micrograms per milliliter
Minimum Serum Concentration at Steady State (Cmin,ss) of Belimumab for Participants Weighing >= 50 kg
Micrograms per milliliterBelimumab 200 mg/mL Every Week
Minimum Serum Concentration at Steady State (Cmin,ss) of Belimumab for Participants Weighing >= 50 kg82.63 ± 28.69
PrimaryMinimum Serum Concentration at Steady State (Cmin,ss) of Belimumab for Participants Weighing Between 30 kg and < 50 kg

Blood samples were collected at indicated time points for PK analysis of belimumab. Cmin,ss of belimumab for participants weighing 30 kg and \< 50 kg has been reported.

Time frame:
Pre-dose on Days 1, 11, and 71, and post-dose on Days 4, 74, and 81
Reported as:
Geometric mean · Micrograms per milliliter
Minimum Serum Concentration at Steady State (Cmin,ss) of Belimumab for Participants Weighing Between 30 kg and < 50 kg
Micrograms per milliliterBelimumab 200 mg/mL Every 10 Days
Minimum Serum Concentration at Steady State (Cmin,ss) of Belimumab for Participants Weighing Between 30 kg and < 50 kg70.71 ± 20.14
PrimaryMinimum Serum Concentration at Steady State (Cmin,ss) of Belimumab for Participants Weighing Between 15 kg and < 30 kg

Blood samples were collected at indicated time points for PK analysis of belimumab. Cmin,ss of belimumab for participants weighing 15 kg and \< 30 kg has been reported. As the first dose of belimumab was administered on Day 1, Week 12 post-dose correlates to Day 1 plus 84 days, i.e., Day 85.

Time frame:
Pre-dose on Days 1, 15, and 71, and post-dose on Days 4, 74, and 85
Reported as:
Geometric mean · Micrograms per milliliter
Minimum Serum Concentration at Steady State (Cmin,ss) of Belimumab for Participants Weighing Between 15 kg and < 30 kg
Micrograms per milliliterBelimumab 200 mg/mL Every 2 Weeks
Minimum Serum Concentration at Steady State (Cmin,ss) of Belimumab for Participants Weighing Between 15 kg and < 30 kg80.95 ± NA
PrimaryMaximum Serum Concentration During the Dosing Interval at Steady State (Cmax,ss) of Belimumab for Participants Weighing >= 50 kg

Blood samples were collected at indicated time points for PK analysis of belimumab. Cmax,ss of belimumab for participants weighing \>= 50 kg has been reported. As the first dose of belimumab was administered on Day 1, Week 12 post-dose correlates to Day 1 plus 84 days, i.e., Day 85.

Time frame:
Pre-dose on Days 1, 8, and 78, and post-dose on Days 4, 81, and 85
Reported as:
Geometric mean · Micrograms per milliliter
Maximum Serum Concentration During the Dosing Interval at Steady State (Cmax,ss) of Belimumab for Participants Weighing >= 50 kg
Micrograms per milliliterBelimumab 200 mg/mL Every Week
Maximum Serum Concentration During the Dosing Interval at Steady State (Cmax,ss) of Belimumab for Participants Weighing >= 50 kg93.36 ± 25.80
PrimaryMaximum Serum Concentration During the Dosing Interval at Steady State (Cmax,ss) of Belimumab for Participants Weighing Between 30 kg and < 50 kg

Blood samples were collected at indicated time points for PK analysis of belimumab. Cmax,ss of belimumab for participants weighing between 30 kg and \< 50 kg has been reported.

Time frame:
Pre-dose on Days 1, 11, and 71, and post-dose on Days 4, 74, and 81
Reported as:
Geometric mean · Micrograms per milliliter
Maximum Serum Concentration During the Dosing Interval at Steady State (Cmax,ss) of Belimumab for Participants Weighing Between 30 kg and < 50 kg
Micrograms per milliliterBelimumab 200 mg/mL Every 10 Days
Maximum Serum Concentration During the Dosing Interval at Steady State (Cmax,ss) of Belimumab for Participants Weighing Between 30 kg and < 50 kg87.15 ± 15.91
PrimaryMaximum Serum Concentration During the Dosing Interval at Steady State (Cmax,ss) of Belimumab for Participants Weighing Between 15 kg and < 30 kg

Blood samples were collected at indicated time points for PK analysis of belimumab. Cmax,ss of belimumab for participants weighing between 15 kg and \< 30 kg has been reported. As the first dose of belimumab was administered on Day 1, Week 12 post-dose correlates to Day 1 plus 84 days, i.e., Day 85.

Time frame:
Pre-dose on Days 1, 15, and 71, and post-dose on Days 4, 74, and 85
Reported as:
Geometric mean · Micrograms per milliliter
Maximum Serum Concentration During the Dosing Interval at Steady State (Cmax,ss) of Belimumab for Participants Weighing Between 15 kg and < 30 kg
Micrograms per milliliterBelimumab 200 mg/mL Every 2 Weeks
Maximum Serum Concentration During the Dosing Interval at Steady State (Cmax,ss) of Belimumab for Participants Weighing Between 15 kg and < 30 kg109.59 ± NA
SecondaryNumber of Participants With Adverse Events (AEs), Serious AEs (SAEs), and AEs of Special Interest (AESIs) Through Week 12

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect in the offspring of a study participant; or other situations as per medical and scientific judgement of the Investigator. AESIs defined in the protocol included post-injection systemic reactions and hypersensitivity reactions, infections of special interest, malignancies, and depression, suicidality, or self-injury. Number of participants with AEs, SAEs, and AESIs has been reported.

Time frame:
Up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), and AEs of Special Interest (AESIs) Through Week 12
ParticipantsBelimumab 200 mg/mL
AEs13
SAEs0
AESIs0

Adverse events

Collected over All-cause mortality, SAEs, and non-SAEs were collected up to 28 weeks (treatment: up to 12 weeks and follow-up: up to 16 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Belimumab 200 mg/mL0/16 (0%)0/16 (0%)13/16 (81.3%)
Most frequent other events
Showing 10 of 19
Most frequent other events
EventBelimumab 200 mg/mL
Upper respiratory tract infectionInfections and infestations9/16
BronchitisInfections and infestations3/16
Hepatic function abnormalHepatobiliary disorders2/16
Bacterial infectionInfections and infestations1/16
ConjunctivitisInfections and infestations1/16
Mycoplasma infectionInfections and infestations1/16
Tinea versicolourInfections and infestations1/16
TonsillitisInfections and infestations1/16
Viral infectionInfections and infestations1/16
DiarrhoeaGastrointestinal disorders1/16

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)Belimumab 200 mg/mL
Mean12.9 ± 2.55
Sex: Female, Male
Sex: Female, Male(Participants)Belimumab 200 mg/mL
Female11
Male5
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Belimumab 200 mg/mL
Asian - East Asian Heritage16
08

Study locations

6 sites
  • GSK Investigational Site
    Beijing, 100045, China
  • GSK Investigational Site
    Changsha, 410007, China
  • GSK Investigational Site
    Hangzhou, 310052, China
  • GSK Investigational Site
    Nanjing, 210011, China
  • GSK Investigational Site
    Shanghai, 361006, China
  • GSK Investigational Site
    Suzhou, 215007, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Oct 2024, 15 months.

Results were first posted in Nov 2025, 1 year after primary completion.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's 15 months is below that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2023
First posted
Jun 23, 2023
StartActual
Jul 7, 2023
Primary completionActual
Oct 30, 2024
CompletionActual
Oct 30, 2024
Results first posted
Nov 14, 2025
Last update
Nov 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05917288
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 23, 2023
Start date
Jul 7, 2023
Primary completion
Oct 30, 2024
Completion
Oct 30, 2024
Results posted
Nov 14, 2025
Last update
Nov 14, 2025

Study contacts

GSK Clinical Trials
study director · GSK Clinical Trials

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belimumab

Start the discussion